[mausmish]

I didn't find the results of this study to be compelling. In addition to the very small sample size (22), the following info from the report makes me question the validity of the conclusions of the 5 vs. 7 question:

"Yet the researchers are not so certain. They note that the patients in their study had noticeably weaker immune systems – based on their absolute neutrophil counts – compared to patients in the two major trials that used the seven-day subcutaneous Vidaza regimen.

And, in fact, a key difference in the survival of the patients in the different studies is that almost one quarter of the Washington University study patients died – primarily due to infections – within two months of starting their Vidaza therapy. In comparison, there were very few early deaths in the two seven-day regimen trials."

They say the response rates and response durations are similar for the two regimens. The big difference was in median survival duration. But those results are skewed by the lower immune systems and early deaths by infection.